Business
MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
MilliporeSigma: Sole Testing Provider for Genetix' Gene Therapies MilliporeSigma supports the commercialization of Genetix Biotherapeutics' FDA-approved gene therapies. Burlington, Massachusetts, May 07, 2026 (GLOBE NEWSWIRE) -- MilliporeSigma enters five-year agreement to provide end-to-end testing services for Genetix Biotherapeutics’ commercial therapiesPartnership builds on more than a decade of collaboration, reinforcing MilliporeSigma’s role in supporting the safe, reliable commercializati
About this update from Merck Kgaa
[{"type":"text","content":"MilliporeSigma: Sole Testing Provider for Genetix' Gene Therapies","length":69,"tagName":"p"},{"type":"image","alt":"MilliporeSigma supports the commercialization of Genetix Biotherapeutics' FDA-approved gene therapies.","displaySize":"","headline":null,"caption":"MilliporeSigma supports the commercialization of Genetix Biotherapeutics' FDA-approved gene therapies.","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":914,"url":"https://media.zenfs.com/en/globenewswire.com/dedd3be82aa9160a0149a3c2c8eda91f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RIiqf3yizsYJqGog46dsrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY4Ng--/https://media.zenfs.com/en/globenewswire.com/dedd3be82aa9160a0149a3c2c8eda91f","width":960,"height":686},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/99mSgATUrdMg6Xa.cnDQsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQ1Nw--/https://media.zenfs.com/en/globenewswire.com/dedd3be82aa9160a0149a3c2c8eda91f","width":640,"height":457},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/prMud5IY36SASXToKXFghQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNzE0/https://media.zenfs.com/en/globenewswire.com/dedd3be82aa9160a0149a3c2c8eda91f","width":1200,"height":857}}},{"type":"text","content":"Burlington, Massachusetts, May 07, 2026 (GLOBE NEWSWIRE) --","length":59,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"MilliporeSigma enters five-year agreement to provide end-to-end testing services for Genetix Biotherapeutics’ commercial therapies","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Partnership builds on more than a decade of collaboration, reinforcing MilliporeSigma’s role in supporting the safe, reliable commercialization of novel modalities","length":163,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":293,"olType":false},{"type":"text","content":"MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a five-year agreement with Genetix Biotherapeutics to provide analytical and biosafety release testing services for its portfolio of FDA-approved gene therapies.","length":312,"tagName":"p"},{"type":"text","content":"The agreement covers three FDA-approved gene therapies developed by Genetix to treat sickl...